Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Acquires $79,600.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director John B. Bode bought 10,000 shares of Zevra Therapeutics stock in a transaction on Wednesday, March 19th. The shares were purchased at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the acquisition, the director now owns 40,000 shares in the company, valued at $318,400. The trade was a 33.33 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $8.01 on Monday. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The firm has a market capitalization of $433.47 million, a price-to-earnings ratio of -4.07 and a beta of 1.98. The business has a 50 day simple moving average of $7.90 and a 200 day simple moving average of $8.19.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The business had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. On average, equities research analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ZVRA. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Guggenheim raised their price target on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of Zevra Therapeutics in a report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday, March 13th. Finally, JMP Securities set a $18.00 price objective on Zevra Therapeutics in a research note on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $22.29.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ZVRA. MetLife Investment Management LLC lifted its stake in shares of Zevra Therapeutics by 8.1% in the 3rd quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock worth $159,000 after acquiring an additional 1,717 shares during the period. IFG Advisors LLC lifted its position in Zevra Therapeutics by 10.0% in the fourth quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock worth $242,000 after purchasing an additional 2,650 shares during the period. Invesco Ltd. boosted its stake in Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company’s stock valued at $153,000 after purchasing an additional 3,007 shares in the last quarter. Corebridge Financial Inc. increased its position in shares of Zevra Therapeutics by 16.9% during the 4th quarter. Corebridge Financial Inc. now owns 26,294 shares of the company’s stock valued at $219,000 after purchasing an additional 3,801 shares during the period. Finally, Squarepoint Ops LLC raised its stake in shares of Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock worth $138,000 after buying an additional 4,384 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.